Cefaly gets FDA approval for marketing - First medical device approved to prevent migraine
U.S. Food and Drug Administration allowed marketing of the first device, Cefaly-manufactured by STX-Med in Belgium, as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain.

Novel biological markers have discovered by researchers from Finland and Estonia that are strongly indicative of risk of dying from any disease within the near future. Blood samples from over 17000 generally healthy people were screened for more than a hundred different biomolecules. The health status of these study volunteers was followed for several years. The researchers looked for measures in the blood that could reflect who had died within the following 5 years after the blood sample was taken. In a study published in PLOS Medicine, they describe identification of four such biomarkers of death.
The expert committee submitted report to ministry of health and family welfare, Government of India on amendment of relevant rules in the Drugs and Cosmetics Act 1940 to include stem cells and other cell based products (SCCPs) as New Drugs.
The USFDA approved Chelsea Therapeutics's product Northera capsules (droxidopa), orphan-product, for the treatment of neurogenic orthostatic hypotension (NOH) which is rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson's disease, multiple-system atrophy,
